Combination therapy of recalcitrant severe psoriasis with psoriatic arthritis, diabetes nephropathy, and liver cirrhosis.
Sebastian ZimmerMohamad GoldustShashank BhargavaJoanna WegnerStephan GrabbePetra Staubach-RenzPublished in: Journal of cosmetic dermatology (2021)
There are no data supporting the combination of apremilast and etanercept in the management of recalcitrant cases of moderate-to-severe psoriasis and multiple comorbidities including psoriatic arthritis, diabetic nephropathy, and cirrhosis. In patients who do not respond to multiple approaches for the treatment of psoriasis, combination therapy with biologic agents and new systemic medications may lead to dramatic disease control.
Keyphrases
- combination therapy
- diabetic nephropathy
- rheumatoid arthritis
- early onset
- type diabetes
- atopic dermatitis
- cardiovascular disease
- electronic health record
- juvenile idiopathic arthritis
- ankylosing spondylitis
- high intensity
- drug induced
- big data
- glycemic control
- systemic lupus erythematosus
- artificial intelligence
- weight loss